0.41Open0.41Pre Close0 Volume883 Open Interest310.00Strike Price0.00Turnover43.37%IV23.68%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.41Extrinsic Value100Contract SizeAmericanOptions Type0.0375Delta0.0029Gamma612.15Leverage Ratio-0.0465Theta0.0062Rho22.97Eff Leverage0.0537Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet